Paul R. Edick - 31 Jan 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chairman and Chief Executive Officer, Director
Signature
/s/ Beth Hecht as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
4
Filing time
01 Feb 2023, 15:13:39 UTC
Previous filing
14 Dec 2022
Next filing
09 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +750,000 +49% $0.000000 2,278,064 31 Jan 2023 Direct F1
holding XERS Common Stock 33,430 31 Jan 2023 By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Chairman and Chief Executive Officer